Mechanical circulatory support in patients with cardiogenic shock not secondary to cardiotomy: a network meta-analysis.

Authors:
Benenati S; Toma M; Canale C; Vergallo R; Bona RD and 6 more

Journal:
Heart Fail Rev

Publication Year: 2021

DOI:
10.1007/s10741-021-10092-y

PMCID:
PMC9033692

PMID:
33677732

Journal Information

Full Title: Heart Fail Rev

Abbreviation: Heart Fail Rev

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Cardiology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Conflict of interestDr. Ameri reports personal fees from Novartis, personal fees from Astra Zeneca, personal fees from Vifor, personal fees from Daiichi-Sankyo, personal fees from Boehringer Ingelheim, personal fees from Janssen, personal fees from Merck Sharp & Dohme, and personal fees from GlaxoSmithKline, outside the submitted work; Dr. Porto reports grants and personal fees from AstraZeneca, personal fees from Daiichi Sankyo, personal fees from Terumo Corporation, personal fees from Biotronik, personal fees from Bayer, personal fees from Amgen, and personal fees and non-financial support from Abiomed, outside the submitted work; Dr. Canepa reports grants and personal fees from Pfizer, personal fees from Novartis, personal fees from Akcea Therapeutics, and personal fees from Sanofi Genzyme, outside the submitted work; Dr. Crimi reports personal fees from Philips healthcare, outside the submitted work; other authors have nothing to disclose. Conflict of interest Dr. Ameri reports personal fees from Novartis, personal fees from Astra Zeneca, personal fees from Vifor, personal fees from Daiichi-Sankyo, personal fees from Boehringer Ingelheim, personal fees from Janssen, personal fees from Merck Sharp & Dohme, and personal fees from GlaxoSmithKline, outside the submitted work; Dr. Porto reports grants and personal fees from AstraZeneca, personal fees from Daiichi Sankyo, personal fees from Terumo Corporation, personal fees from Biotronik, personal fees from Bayer, personal fees from Amgen, and personal fees and non-financial support from Abiomed, outside the submitted work; Dr. Canepa reports grants and personal fees from Pfizer, personal fees from Novartis, personal fees from Akcea Therapeutics, and personal fees from Sanofi Genzyme, outside the submitted work; Dr. Crimi reports personal fees from Philips healthcare, outside the submitted work; other authors have nothing to disclose."

Evidence found in paper:

"Funding Open access funding provided by Università degli Studi di Genova within the CRUI-CARE Agreement."

Evidence found in paper:

"This meta-analysis was registered on PROSPERO (CRD42020189859) and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) recommendations [] (Appendix Table )."

Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025